

Cardiovascular (CV) Outcome Trials: SGLT2

Adapted from Cardiac benefits in Diabetes Therapy: Comparing SGLT2 Inhibitors and GLP-1 Agonists

By Samuel Grossman, BS Pharm, PharmD, CDE, FADE

Name of trial	Patient	Groups	Outcomes: ASCVD	Outcomes: HF
DECLARE DECLARE-TIMI 58	>17,000 with CV	Dapagliflozin vs. Placebo	Noninferiority to MACE vs. placebo	Significant lower rates hospitalization for HF & CV death vs. placebo Less renal events & increase in DKA vs. placebo

MACE: major adverse cardiac events

DKA: Diabetic ketoacidosis

References:

- Diabetes Care 2019;42 (suppl. 1):s115-s119
- http://www.onlinejacc.org/content/accj/73/9_Supplement_1/1.full.pdf accessed 9/19